Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07672431 · ClinicalTrials.gov registry record · NA
Study of the TheraBionic P1 Device in Patients With Metastatic Triple Negative Breast Cancer After Progression
A NA study, sponsored by Barbara Ann Karmanos Cancer Institute.
- Not yet
- Registry status
- NA
- Development phase
- 24
- Enrollment target
NCT07672431 is a NA study that has not yet begun recruiting, run by Barbara Ann Karmanos Cancer Institute. The registered enrollment target is 24 participants.
The verdict
NCT07672431, a NA study, has not yet begun recruiting, sponsored by Barbara Ann Karmanos Cancer Institute.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 24 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to learn if adding the TheraBionic P1 device to standard of care third line treatment for adult women with metastatic triple negative breast cancer (mTNBC) who have failed, not tolerated, or progressed on standard first- and second-line treatment options can work better than the standard of care alone. The main questions it aims to answer is: * will the addition of the TheraBionic P1 device to standard of care third line treatment affect progression free and overall survival in these participants
Interventions
- DEVICE TheraBionic P1
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2026-09 |
| Est. Completion | 2028-12-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07672431
The ClinicalTrials.gov registry entry for NCT07672431 describes a study currently listed as not yet recruiting, categorized as NA. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Barbara Ann Karmanos Cancer Institute, which has 139 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TheraBionic P1 is the first listed.
NCT07672431 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07672431 about?
NCT07672431 is a clinical study titled "Study of the TheraBionic P1 Device in Patients With Metastatic Triple Negative Breast Cancer After Progression". The goal of this clinical trial is to learn if adding the TheraBionic P1 device to standard of care third line treatment for adult women with metastatic triple negative breast cancer (mTNBC) who have failed, not tolerated, or progressed on standard first- and second-line treatment options can work b...
What is the current status of trial NCT07672431?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 24 participants. The study started on 2026-09. Estimated completion is 2028-12-31.
What interventions are being tested in trial NCT07672431?
The interventions under investigation include: TheraBionic P1 (DEVICE).
Who is sponsoring clinical trial NCT07672431?
This trial is sponsored by Barbara Ann Karmanos Cancer Institute, which has 139 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.